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Abstract
Background: Esthesioneuroblastoma (ENB) is a rare, aggressive tumor with no established treatment in children.
We analyzed a series of pediatric ENB patients with the aim of improving our knowledge of this disease.
Methods: 9 patients (6 males; age 0.9-18 years, median 9.9) were identified by searching the AIEOP (Italian
Association of Pediatric Hematology and Oncology) registry and the national databases of rare tumors, soft tissue
sarcomas (STS) and neuroblastomas. The data on the cases included in STS treatment protocols were collected
prospectively and histology was centrally reviewed; the data and histology concerning the other children were
reviewed for the purpose of this analysis.
Results: All tumors occurred in the sinonasal region with bone erosion (7 patients) and intracranial (4) or
intraorbital (4) extension. Three patients were in Kadish stage B, and 6 in stage C. Complete tumor resection was
very difficult to achieve, but adding chemotherapy and radiotherapy enabled tumor control in 8 patients. Response
to chemotherapy was evident in 5/7 evaluable cases. Radiotherapy (48.5-60 Gy) was delivered in all children but
one, due to early disease progression. With a median follow-up of 13.4 years (range 9.2-22.9), 7 patients are alive in
1
st and one in 2nd complete remission. All surviving patients developed treatment-related sequelae, the most
frequent being endocrine dysfunctions (4 patients) and craniofacial growth impairments (4 patients).
Conclusions: Our findings confirm that ENB in children has an aggressive presentation, but multimodal therapy
can cure most patients. Our results are encouraging but future strategies must optimize treatment in terms of
survival and related morbidities.
Keywords: Esthesioneuroblastoma, Olfactory neuroblastoma, Rare tumors, Nasal tumors, Chemotherapy, Radiother-
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Background
Esthesioneuroblastoma (ENB), or olfactory neuroblas-
toma, is a rare, aggressive tumor of the sinonasal region
originating from olfactory neuroepithelium. Its incidence
is approximately 0.4-1/1,000,000 population per year
and, though it can occur at any age, its incidence peaks
in the second and fifth decades of life [1,2]. No gender
predilection has been reported and its etiology is
unknown, but an infectious genesis has been suggested
because the tumor contains viral particles [3,4].
In pediatric age, the estimated incidence of ENB is
0.1/100,000 children up to 15 years of age, but it is the
most common cancer of the nasal cavity, accounting for
28% of a series of 47 cases registered in the Surveillance,
Epidemiology and End Results (SEER) database from
1973 to 2002 [2,5]. * Correspondence: gianni.bisogno@unipd.it
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any medium, provided the original work is properly cited.ENB in younger patients seems to have a more aggres-
sive presentation than in adults with a larger proportion
of cases with advanced disease.
Treatment decisions are based mainly on experience
gained in adults, but implementing local measures such
as radical surgery and high-dose radiotherapy pose spe-
cific problems in pediatric age.
A national-scale initiative called the TREP project
(Tumori Rari in Età Pediatrica, Rare Tumors in Pediatric
Age) was launched in Italy in 2000 with the aim of
improving the clinical management of children with
very rare cancers (defined as pediatric solid malignancies
with an annual incidence < 2/million and not considered
in other clinical trials) and contributing to the related
basic research [6]. As part of this scheme, the present
study was designed to describe the clinical characteris-
tics, treatment and outcome of ENB patients treated at
Italian pediatric oncology centers.
Methods
All patients under 18 years of age registered by AIEOP
centers with a diagnosis of ENB were included in this
analysis. The cases were identified by searching the
AIEOP hospital-based registry (where all Italian pedia-
tric oncology centers register the cases they diagnose),
the TREP project database (from 2000 onwards), and
the database managed by the Italian Working Groups
on Neuroblastoma and Soft Tissue Sarcoma. Only
patients diagnosed from 1980 to December 2008 were
considered to allow for an adequate follow-up.
Tumors were defined according to the staging system
proposed by Kadish and modified by Morita, as follows:
A - tumors confined to the nasal cavity; B - tumors
infiltrating the paranasal cavities; C - tumors extending
beyond the nasal and paranasal cavities; D - tumors
with metastases [7,8]. The disease was also staged
according to the TNM system, where T1 means tumors
confined to the organ or tissue of origin, and T2 lesions
invade contiguous structures; T1 and T2 are further
classified as A or B by tumor diameter < or > 5 cm,
respectively; N1 means regional lymph node involve-
ment; and M1 the presence of distant metastases.
T h e r ew e r en os p e c i f i cg u i d e l i n e sf o rt r e a t i n gE N Bs o
children were treated on the basis of the existing litera-
ture and, for pragmatic reasons, included in the ongoing
Italian protocols for rhabdomyosarcoma (RMS) (which
also included soft tissue neuroectodermal tumors) or
neuroblastoma (NBL).
Informed consent to the treatment and to data collec-
tion and analysis was obtained for all patients according
to institutional guidelines at the time of enrolling
patients in the protocols.
Response to chemotherapy was defined as follows:
complete response (CR) - clinically or histologically
confirmed complete disappearance of disease; partial
response (PR) - at least a two-thirds reduction in tumor
volume; minor response (MR) - reduction greater than
one-third but less than two-thirds; no response or stable
disease (SD) - less than one-third reduction in tumor
volume; progressive disease (PD) - increase in tumor
size or detection of new lesions.
The data on the cases included in the protocols for
RMS were collected prospectively and their histology
was centrally reviewed; the data and histology on the
other children were reviewed for the purpose of this
analysis. Response to chemotherapy was re-evaluated on
the basis of radiological reports in the two cases for
whom no radiological findings were available.
The long-term sequelae were only ascertained by con-
tacting the clinical investigators at the various centers;
no additional investigations were conducted on possible
late effects for the purpose of this study.
Results
Overall, 11 patients with ENB were registered, but full
details were only available for 9 of them (6 males; age
0.9-18 years, median 9.9). The patients’ demographic
data are shown in Table 1.
Symptoms were non-specific and usually involved
nasal obstruction, headache and epistaxis. One child had
an epileptic episode and revealed a mass in the olfactory
region that extended intracranially.
In addition to computed tomography or magnetic
resonance imaging, metaiodobenzylguanidine scans were
obtained for 4 patients but none of them were positive.
The initial diagnosis was NBL in 2 cases and PNET in
1, but was changed to ENB after central review soon
afterwards. Nearly all tumors were large (> 5 cm in
maximum diameter) and aggressive, with bone erosion
(7 patients) and intracranial (4) or intraorbital (4) exten-
sion. Regional lymph nodes were involved in 3 children.
The Kadish stage was consequently C in 6 patients and
Bi n3 .
Treatment
The treatments administered are summarized in Table
2. At diagnosis, tumor resection was attempted in 4
cases but was always incomplete, while only a diagnostic
biopsy was obtained in 4. Lymph node biopsy was per-
formed in one case. No major postoperative complica-
tions were reported. All patients received multidrug
chemotherapy: 6 were enrolled in protocols proposed
for children with RMS and 3 in protocols for children
with NBL. The regimens changed over time but the
children on the RMS protocol mainly received che-
motherapy based on the association of vincristine, dox-
orubicin, ifosfamide, actinomycin D (VAdIA), while
those on the NBL protocol were given cycles with
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Page 2 of 5Table 1 Clinical characteristics of 9 patients with esthesioneuroblastoma
Pt. Sex/age at
dgn (years)
Symptoms Primary site Tumor extension Tumor
size
TNM Kadish
stage
1 M/4 Seizures Rhinopharynx Intracranial, bone erosion, cervical lymph nodes > 5 cm T2b,
N1, M0
C
2 M/2 Exophthalmos Nasal cavity, rhinopharynx and
ethmoid sinuses
Orbital cavity, submandibular lymph node, bone
erosion
> 5 cm T2b,
N1, M0
C
3 F/16 Recurrent
epistaxis
Paranasal sinuses - > 5 cm T1b,
N0, M0
B
4 M/10 None Nasal cavity, rhinopharynx and
maxillary sinuses
Bone erosion < 5 cm T2a,
N0, M0
B
5 M/1 Recurrent
epistaxis
Nasal cavity, ethmoid sinuses Intracranial, bone erosion > 5 cm T2b,
N0, M0
C
6 M/11 Nasal
obstruction
Nasal cavity, maxillary and
ethmoid sinuses
- > 5 cm T2b,
N0, M0
B
7 M/5 Cranial nerve
palsy
Nasal cavity
pterygomandibular,
infratemporal fossae
Intracranial, orbital cavity, bone erosion > 5 cm T2b,
N0, M0
C
8 F/18 Proptosis Nasal cavity Intracranial, orbital cavity, retromandibular and
laterocervical lymph nodes, bone erosion
> 5 cm T2b,
N1, M0
C
9 F/17 Headache Maxillary and ethmoid sinuses Orbital cavity, bone erosion > 5 cm T2b,
N0, M0
C
Pt: patient; dgn: diagnosis; M: male; F: female.
Table 2 Treatment details for 9 patients with esthesioneuroblastoma
Pt. Protocol
type
Initial
surgery
CT (No.
of
cycles)
Response
to CT
Delayed
surgery
RT
(dose)
Outcome
(years after
diagnosis)
Long-term sequelae
1 RMS Macroscopic
residuals
VAdIA
(9)
PR No No DOD (0.7) -
2 RMS Biopsy VAdIA
(12)
CR No Yes
(53
Gy)
NED (11.5) GH deficit, hypogonadism, hypothyroidism, chronic
sinusitis, hypovision and cataract, hearing loss, dental
abnormalities, facial bones hypoplasia
3 RMS Biopsy VAdIA
+
Carbo/E
(5)
PR Microscopic
residuals
Yes
(50
Gy)
NED (13) Palate deformity
4 RMS Biopsy VAdIA
(12)
MR Complete
resection
Yes
(60
Gy)
NED (14) Hypothyroidism, xerostomia, oligospermia
5 RMS Microscopic
residuals
VAdIA
(9)
NE No Yes*
(42
Gy)
NED (9.2) Chronic headache, hypothyroidism, attention-deficit/
hyperactivity disorder
6 NBL Macroscopic
residuals
VAdC +
CDDP/E
(6)
SD Microscopic
residuals
Yes
(48
Gy)
NED (11.1) loss of sense of smell, facial bone hypoplasia, recurrent
keratoconjunctivitis, maculopathy
7 NBL Biopsy VAdCA
+
CDDP/E
+
i.t. MTX
(15)
PR No Yes
(60
Gy)
NED (23) Amaurosis, hypothyroidism, GH deficiency, xerostomia,
facial bones hypoplasia
8 NBL Lymph node
biopsy
VAdC/
CDDP
(7)
CR No Yes
(47
Gy)
NED (20.2) Peripheral neuropathy
9 RMS Macroscopic
residuals
VAdC
(12)
NE No Yes
(60
Gy)
NED (17.1) Chronic sinusitis
Pt: patient; CT: chemotherapy; RT: radiotherapy; RMS: rhabdomyosarcoma; V: vincristine, Ad:adriamycin, I: ifosfamide, A actinomycin-D; PR: partial response; DOD:
dead of disease; CR: complete response; Gy: grays; NED: not evidence of disease; GH: growth hormone; Carbo: carboplatin; E: etoposide; PR: partial response; MR:
minor response; NE: not evaluable; NBL: neuroblastoma; C: cyclophosphamide; CDDP: cisplatin; SD: stable disease; i.t. MTX: intrathecal methotrexate
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alternated with the cisplatin-etoposide combination. The
duration of chemotherapy varied considerably, with a
total of 5 to 15 cycles being administered.
*pt No. 5 received radiotherapy after tumor relapse.
Major tumor shrinkage was evident after chemotherapy
in 5 of the 7 cases evaluable (2 CR and 3 PR). Response
was not evaluable in 2 patients because the tumor was
resected at diagnosis in one (No. 5), and because one
child had already been irradiated during initial che-
motherapy (No. 9). Delayed tumor resection was
attempted in 3 patients and was complete in one. Radio-
therapy (47-60 Gy) was delivered during the first-line
treatment to all but two children: one progressed just
before starting radiotherapy; the other was a very young
child who was irradiated only after tumor relapse.
Outcome
With a median follow-up of 13.4 years (range 9.2-22.9),
7 patients are alive in 1
st CR. The young child who was
not irradiated during first-line therapy (No. 5) relapsed
in the locoregional lymph nodes 20 months after com-
pleting the treatment, but achieved a 2
nd long-lasting
CR after tumor resection and further chemo- and radio-
therapy. The disease progressed in one patient (No. 1),
who died 9 months after diagnosis. The 5-year progres-
sion-free and overall survival (OS) rates were thus 77.8%
(36.6%-93.9%) and 88.9% (43.3%-98.4%), respectively.
The most frequent long-term adverse effects were
endocrine dysfunctions and craniofacial growth impair-
ment (affecting 4 patients each). Other reported seque-
lae included ocular damage (2), xerostomia (2), chronic
sinusitis (2), damage to permanent teeth (1), loss of the
sense of smell (1), and behavioral disorders (1). Fertility
problems and neuropathies relating to the chemotherapy
administered were also reported.
Discussion
Our report confirms that ENB is very rare in pediatric
age and that its behavior is aggressive, since most chil-
dren presented with locally disseminated disease. As
localized ENB (Kadish stage A) seems to be rare in chil-
dren, and our series only contained tumors in Kadish
stages B and C, our discussion focuses on locally
advanced ENB.
Tumor resection is generally the first therapeutic mea-
sure in adults with ENB (though this often requires a
craniofacial approach), followed by radiotherapy [9].
Chemotherapy is mainly reserved for patients with
advanced, recurrent or metastatic disease. Preoperative
radiotherapy in doses in the range of 55 to 65 Gy has
been preferred by some authors for stage C ENB [10].
These procedures are highly aggressive, however, and
skull base surgery is particularly difficult in children
because of the small size of the area, and because of the
bone and neurovascular structures located in the cranio-
facial region. Up to one in three patients therefore risk
postoperative morbidities, including complications invol-
ving the local wounds, the central nervous system (e.g.
cerebrospinal fluid leakage and meningitis) and the ocu-
lar orbit. Postoperative mortality has also been reported
in up to 5% of patients [11]. Radiotherapy may also
cause significant late effects in children, including cra-
niofacial growth impairment and damage to the perma-
nent teeth, endocrine dysfunctions, and loss of the sense
of smell [12]. In our series, multiple-agent chemotherapy
was adopted systematically and judged preferable to
invasive surgery as an initial approach. This had numer-
ous advantages for the patients, since no major surgical
complications were reported and tumor shrinkage after
chemotherapy meant that delayed surgery could be less
aggressive. Unfortunately, complete tumor resection was
still very difficult to achieve, but our experience suggests
that chemotherapy and radiotherapy may be enough to
control postoperative residuals, and some patients were
cured without any major surgery.
In our experience radiotherapy is the mainstay of
treatment for ENB, as it is for other parameningeal
pediatric tumors for which surgery cannot be considered
oncologically complete. Two young children in our ser-
ies were not irradiated and both relapsed locally, but
one of them was cured thanks to further treatment,
including radiotherapy. Experiences and other data in
the literature indicate that irradiation should not be
withheld, but future studies should address whether a
major response to initial chemotherapy might be enough
to reduce the burden of irradiation and its likely long-
term sequelae. New techniques, such as proton therapy,
may also be helpful to limit the side effects of treatment
[13,14].
Our findings show that ENB in children can be con-
sidered a chemosensitive tumor. This is in agreement
with recent reports of tumor size reductions when che-
motherapy was given preoperatively [12,15]. The agents
most often used in children are doxorubicin, cyclopho-
sphamide/ifosfamide, vincristine, and etoposide, whereas
platinum-based regimens are adopted in adults [16].
T h ea b o v ed r u g sw e r eu s e di no u rs t u d i e st o o ,a n d
gave rise to a satisfactory response rate. The limited
number of children in our series made it impossible to
analyze the different regimens separately or make any
more precise recommendations on the type and dura-
tion of chemotherapy. This could be done by consider-
ing other experiences too, comparing and discussing our
experience with those of other national groups inter-
ested in rare pediatric tumors. This is one of the main
future goals of the TREP Project. In our opinion, the
overall strategy for unresectable tumors may be similar
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namely RMS, for which intensive chemotherapy and
early radiotherapy are recommended.
The survival results reported here are higher than
those described in previously-published series. This may
be due to the systematic use of a multidisciplinary
approach in all the patients concerned. It may also be
that ENB is more aggressive in children than in adults
and/or more sensitive to current treatments. This seems
to be the case for other rare tumors that behave differ-
ently in different age groups. Unfortunately, the need
for an aggressive treatment approach can also mean
severe side effects and this issue should be addressed
when planning future treatments.
Conclusion
In conclusion, our findings confirm that ENB has
aggressive features in children, but a multimodal
approach - relying mainly on chemotherapy and radio-
therapy - can cure most patients. This is an encouraging
result, but more data are needed to optimize strategies
for treating pediatric ENB in terms of patient survival
and treatment-related morbidities.
The limited number of ENB patients analyzed in this
collaborative effort as part of the TREP project goes to
show that we need to move from national to interna-
tional cooperative schemes in order to obtain more
solid evidence to guide the treatment of such very rare
tumors as ENB.
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